TrialClinical cancer research : an official journal of the American Association for Cancer Research2022

FDA Approval Summary: Margetuximab plus Chemotherapy for Advanced or Metastatic HER2-Positive Breast Cancer.

Melanie Royce et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.